Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:AGEN

Agenus Q4 2025 Earnings Report

Agenus logo
$3.11 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$3.12 +0.01 (+0.45%)
As of 05/22/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Agenus EPS Results

Actual EPS
$0.56
Consensus EPS
-$1.27
Beat/Miss
Beat by +$1.83
One Year Ago EPS
N/A

Agenus Revenue Results

Actual Revenue
$34.20 million
Expected Revenue
$28.10 million
Beat/Miss
Beat by +$6.11 million
YoY Revenue Growth
N/A

Agenus Announcement Details

Quarter
Q4 2025
Date
3/16/2026
Time
Before Market Opens
Conference Call Date
Monday, March 16, 2026
Conference Call Time
9:30AM ET

Upcoming Earnings

Agenus' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Agenus' Q4 2025 Press ReleasePress Release
(8-K)
Agenus' Q4 2025 Annual reportAnnual report
(10-K)

Agenus Earnings Headlines

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
May 22 at 8:10 AM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/agenus-presents-phase-2-bot-210000643.html
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
May 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260521604737/en/agenus-and-noetik-present-asco-2026-data-linking-ai-analysis-of-routine-pretreatment-tumor-pathology-images-to-response-and-survival-with-botbal-in-mss-metastatic-crc/
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
May 25 at 1:00 AM  |  Weiss Ratings (Ad)
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260515976818/en/agenus-announces-publication-of-phase-1b-botensilimab-and-balstilimab-data-in-post-immunotherapy-hepatocellular-carcinoma-in-liver-cancer/
Agenus (AGEN) price target decreased by 32.61% to 15.81
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/agenus-agen-price-target-decreased-by-32-61-to-15-81/ar-AA23a7Hm
Agenus: Q1 Earnings Snapshot
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/agenus-q1-earnings-snapshot-212746687.html
See More Agenus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email.

About Agenus

Agenus (NASDAQ:AGEN), Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform. Its adjuvant portfolio features QS-21 Stimulon, an immunostimulatory component used to bolster vaccine efficacy. Through strategic collaborations and licensing agreements with leading pharmaceutical companies, the firm has advanced multiple programs into late-stage clinical trials, focusing on refractory and treatment-resistant cancer indications.

Founded in 1994 as Antigenics and rebranded as Agenus in 2016, the company operates research and development activities in the United States and Europe. In 2015, it completed the spin-out of NewLink Genetics, enabling a streamlined focus on its oncology-centric assets. Over the years, Agenus has expanded its scientific platform through targeted acquisitions and partnerships, reinforcing its commitment to innovative immunotherapeutic strategies.

Under the leadership of founder and Chief Executive Officer Garo Armen, Agenus continues to build on its legacy of immuno-oncology innovation. The company is dedicated to translating its platform technologies into combination therapies that address unmet needs in cancer treatment, with the goal of delivering durable responses and improving patient outcomes worldwide.

View Agenus Profile
Earnings Tools